Atlas Trials

Replimune, Inc.

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Replimune, Inc.

RecordFirmDate
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (NCT06581406)Replimune, Inc.2024-12-17
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC (NCT05733598)Replimune, Inc.2024-08-01
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN (NCT05743270)Replimune, Inc.2024-01-30
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (NCT05733611)Replimune, Inc.2023-06-29
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (NCT04735978)Replimune, Inc.2020-12-29
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (NCT04349436)Replimune, Inc.2020-05-15
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (NCT04336241)Replimune, Inc.2019-10-17
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (NCT04050436)Replimune, Inc.2019-10-08
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)Replimune, Inc.2017-09-20

Track Replimune, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.